The concept offers an immensely diversified and innovative range of filling and packing machines for pharmaceutical products, e.g. sterile liquids and powders, non-sterile liquids and powders, pharmaceutical freeze-drying as well as isolation and containment technology
When it comes to manufacturing pharmaceutical products, there can simply be no compromises. Optima Pharma develops and builds filling, sealing and process equipment in accordance with this guiding principle. Its technology is used to process blood plasma products, vaccines, oncology and biotech products in prefilled syringes, vials, IV bottles and carpules. Sterile and non-sterile liquid pharmaceuticals, diagnostic agents and their specific product characteristics combined with special customer requirements set the standard for what technology is implemented.
The core of the machines consists of dosing and sealing systems, complemented by additional functions and process equipment. Washing machines, sterilization tunnels, containment and freeze drying systems, automated loading/unloading and robotic handling complete the comprehensive product range. Optima Pharma specializes in flexibly carrying out complex projects – on time, and on budget. The division’s extensive certifications, the quality of its engineering and the rapid response times of its professional service departments around the globe ensure outstanding long-term equipment effectiveness for customers.
OPTIMA pharma GmbH is a member of the OPTIMA packaging group GmbH with headquarters in Schwäbisch Hall. Other subsidiaries operate in the fields Consumer, Nonwovens and Life science. Founded in 1922, the family business employs a workforce of 1,800 at its three sites in Germany and 13 locations abroad.
Company name: OPTIMA pharma GmbH
Website: www.optima-pharma.com
E-mail: info@optima-pharma.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.